| Patient | Wilma Rudolph |
|---|---|
| Date of birth | 1940-06-23 |
| Identifiers | MRN HR-ML036-SYN-TD; SSN (made up) 000-36-5170 |
| Document date | 1994-07-29 |
| Author | Gloria Haynes-Whitaker, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review three weeks after awake craniotomy, before radiotherapy with temozolomide. [S]
Ms. Rudolph returns three weeks after an awake left frontal craniotomy. The surgeons removed all of the enhancing tumor, stopping at the mapped language sites, and the MRI the next day showed no residual enhancing tumor. Her speech was slower for three days after surgery and then came back to normal; she went home on the third day, having had heparin injections in hospital to prevent clots. She has had no seizure. The right hand is nearly back to normal, though fine buttons are still slow. The physical therapist saw her a week ago and gave her a home exercise program and a cane for uneven ground. She is now on dexamethasone 2 mg twice a day. Her fingerstick glucose readings at home have been 140 to 180 mg/dL after meals, and she is thirsty in the evenings. The pathology is glioblastoma, IDH-wildtype, with MGMT promoter methylation, and the tumor board has reviewed it with Dr. Brzezinski. She has met the radiation oncologist and had her planning scan, and starts radiotherapy with temozolomide on Monday. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Operation | Awake craniotomy with mapping; gross total resection of the enhancing tumor; home on day 3 |
| Pathology | Glioblastoma, IDH-wildtype, CNS WHO grade 4; TERT promoter mutation, EGFR amplification, +7/-10; MGMT promoter methylated |
| Function | Speech normal; right hand nearly normal; walking well |
| Steroid | Dexamethasone 2 mg twice a day; glucose up to 180 mg/dL after meals |
| Next | Radiotherapy 60 Gy in 30 fractions with daily temozolomide from Monday |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; appetite larger on the steroid; weight up 1.6 kg |
| Neurological | Positive | Fine buttons slow with the right hand; no headache, seizure or speech difficulty |
| Endocrine | Positive | Thirsty in the evenings; glucose 140 to 180 mg/dL after meals |
| Musculoskeletal | Negative | No difficulty rising from a chair or climbing stairs |
| Integumentary | Negative | Incision healing; no redness or drainage |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Negative | Mood steadier; PHQ-9 6; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 1994-06-29 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery | One tablet twice a day with breakfast and lunch | Oral route | 1994-06-30 to 1994-07-08 | completed | S |
| Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone | One tablet twice a day | Oral route | 1994-06-30 to 1994-08-12 | completed | S |
| Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering | One tablet twice a day | Oral route | 1994-07-10 to 1994-07-29 | completed | S |
| Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop | One tablet daily for a week, then half a tablet daily for a week | Oral route | 1994-07-29 to 1994-08-12 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1994-07-29 | Body height | 180 | cm | S |
| 1994-07-29 | Body weight | 69.4 | kg | S |
| 1994-07-29 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1994-07-29 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1994-07-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1994-07-29 | Heart rate | 76 | /min | S |
| 1994-07-29 | Respiratory rate | 14 | /min | S |
| 1994-07-29 | Body temperature | 36.6 | Cel | S |
| 1994-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1994-07-29 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1994-07-29 | Leukocytes [#/volume] in Blood by Automated count | 9.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1994-07-29 | Neutrophils [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1994-07-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.1 | 10*3/uL | 1-4 10*3/uL | Normal | S |
| 1994-07-29 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1994-07-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1994-07-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1994-07-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 1994-07-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 1994-07-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1994-07-29 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1994-07-29 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 1994-07-29 | Karnofsky Performance Status score | 90 | {score} | S | ||
| 1994-07-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 1994-07-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 69.4 kg; blood pressure 132/80, pulse 76 |
| Head | Left frontal incision healed, staples out; no swelling or fluid collection |
| Mental status and speech | Fluent, no word-finding pauses; naming and repetition intact |
| Motor | No pronator drift; right grip 5-/5, finger tapping slightly slow; hip flexors 5/5 on both sides; rises from a chair without using her arms |
| Gait | Steady; tandem gait normal |
| Extremities | No leg swelling; calves soft; left calf slightly smaller than the right |
| Psychiatric | Focused and well informed; asks detailed questions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | R29.818 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass. |
| Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | D49.6 | S — Synthetic imaging diagnosis before surgery; superseded by the pathology. |
| Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | C71.1 | S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public. |
| Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | B91 | S — Documented childhood polio (D); the current absence of new symptoms is synthetic. |
| Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | active | confirmed | G93.6 | S — Synthetic finding on the first MRI. |
| Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | active | confirmed | R73.9 | S — Synthetic common effect of dexamethasone; resolved after the taper. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Integrated WHO CNS5 diagnosis | On the surgical specimen | Up to date | Glioblastoma, IDH-wildtype, CNS WHO grade 4: IDH1 R132H negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; +7/-10; CDKN2A deleted; H3 and BRAF wild-type |
| Laboratory | MGMT promoter methylation | On the surgical specimen | Up to date | Methylated |
| Imaging | MRI within 48 hours of surgery | After resection, as the baseline for radiotherapy planning | Up to date | The day after surgery: no residual enhancing tumor |
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Baseline before temozolomide | Completed today | Hemoglobin 12.6 g/dL, white cells 9.6, neutrophils 7.2, lymphocytes 1.1, platelets 248 |
| Laboratory | Kidney and liver tests | Baseline before temozolomide | Completed today | Creatinine 0.82 mg/dL, eGFR 85; ALT 28, AST 22 U/L, bilirubin 0.5 mg/dL, albumin 4.0 g/dL |
| Laboratory | Glucose on dexamethasone | At each visit while on a steroid | Completed today | 168 mg/dL random; home readings 140 to 180 after meals |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Drawn today |
| Medication safety | Dexamethasone taper | As soon as symptoms allow after surgery | Completed today | 2 mg twice a day now; 2 mg daily for a week, 1 mg daily for a week, then stop |
| Medication safety | Pneumocystis pneumonia prophylaxis | Throughout concurrent temozolomide | Ordered | Sulfamethoxazole-trimethoprim three times a week from the first day |
| Medication safety | Antiemetic before temozolomide | Each dose | Ordered | Ondansetron 30 to 60 minutes before the bedtime dose, on an empty stomach |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure before or after surgery; no antiseizure drug |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | Speech normal; right grip 5-/5 with slightly slow finger tapping; gait steady |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | No leg swelling or calf tenderness; hospital prophylaxis given after surgery; no routine prophylaxis at home |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 90 |
| Referral | Physical therapy | After surgery when weakness or fall risk is present | Up to date | Assessed a week ago: home program and a cane for uneven ground |
| Referral | Radiation oncology and clinical trial screening | After the integrated diagnosis | Up to date | Planning scan done; no eligible trial open |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; legs 5/5; no new weakness, fatigue or pain in the polio-affected leg |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6; no thoughts of self-harm |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251 (PMID 34185076) (2021); Mohile NA, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol 2022;40(4):403-426 (PMID 34898238) (2022); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (PMID 15758010) (2005); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Radiotherapy with temozolomide from Monday for six weeks, with weekly blood counts at the radiation clinic. Primary care review at the end of radiotherapy. Call for fever, bruising, a seizure, new weakness or headache. Next scheduled visit 1994-09-14: end of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referral. [S]